MARKET

BLCM

BLCM

Bellicum Pharmaceuticals Inc
NASDAQ
1.020
+0.020
+2.00%
After Hours: 1.020 0 0.00% 16:00 12/02 EST
OPEN
0.9945
PREV CLOSE
1.000
HIGH
1.060
LOW
0.9896
VOLUME
4.01K
TURNOVER
0
52 WEEK HIGH
2.200
52 WEEK LOW
0.9316
MARKET CAP
8.79M
P/E (TTM)
-2.2742
1D
5D
1M
3M
1Y
5Y
Bellicum Pharmaceuticals GAAP EPS of -$0.23, revenue of $1M
Seekingalpha · 11/10 22:02
BRIEF-Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Reuters · 11/10 21:49
Bellicum Pharmaceuticals Q3 EPS $(0.23) Down From $0.07 YoY, Sales $1.00M Down From $5.00M YoY
Benzinga · 11/10 21:41
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate ...
GlobeNewswire · 10/31 21:49
Shuttle, Hempacco lead healthcare gainers; Nuwellis, Liquidia top losers
Gainers: Shuttle Pharmaceuticals (SHPH) +161%. He...
Seekingalpha · 09/01 14:02
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wain...
GlobeNewswire · 09/01 11:30
Bellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Bellicum Pharmaceuticals (BLCM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for ...
Zacks · 08/25 13:55
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.
Zacks · 08/18 13:40
More
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. Its product candidates include BPX-601 and BPX-603. BPX-601, is an autologous GoCAR-T product candidate containing inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). BPX-603 is its dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLCM stock methods without spending real money on the virtual paper trading platform.